COMMUNIQUÉS West-GlobeNewswire

GRI Bio Regains Compliance with Nasdaq
08/07/2024
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the [...]
Courage in the Ring: MS Patient Fights for a Cure
08/07/2024
LONDON, Ontario, July 08, 2024 (GLOBE NEWSWIRE) -- Meet Julia Campbell, a resilient patient confronting multiple sclerosis (MS) head on since her diagnosis early last year. Despite the challenges she’s faced, Julia [...]
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08/07/2024
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing
08/07/2024
GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today [...]
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
08/07/2024
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
08/07/2024
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus [...]
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
08/07/2024
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab [...]
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
08/07/2024
Publication of data relating to RenovoRx’s targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal LOS ALTOS, Calif., July [...]
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
08/07/2024
According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a [...]
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
08/07/2024
The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that [...]
Monthly information on share capital and company voting rights
05/07/2024
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/07/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 juill. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Cronos Group Inc. to Reconvene Virtual 2024 Annual Meeting of Shareholders
05/07/2024
TORONTO, July 05, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it will reconvene its 2024 Annual Meeting of Shareholders on Friday, July 19, 2024 [...]
Report from the Extra General Meeting of Olink Holding AB (publ) on 5 July 2024
05/07/2024
UPPSALA, Sweden, July 05, 2024 (GLOBE NEWSWIRE) -- At the Extra General Meeting (the “EGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), the EGM adopted, inter alia, the following resolutions. For [...]
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
05/07/2024
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for [...]
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/07/2024
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to two new employees of [...]

Pages